ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2013

Elevated Serum Allantoin and Allantoin/uric Acid Ratio as Indicators of Oxidative Stress in Severe Gout and Cardiovascular Comorbidities

Lenka Hasikova1, Petr Kozlik2, Kveta Kalikova3, Petr Dusek4, Marketa Pavlikova1, Blanka Stiburkova5 and Jakub Závada6, 1Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, 3Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, 4Department of Neurology and Centre of Clinical Neuroscience and Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic, Prague, Czech Republic, 5Institute of Rheumatology, Prague, Czech Republic and Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague, Czech Republic, 6Institute of Rheumatology and Charles University, Praha, Czech Republic

Meeting: ACR Convergence 2024

Keywords: Crystal-induced arthritis, Disease Activity, gout, hyperuricemia, Uric Acid, Urate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Uric acid (UA) can be non-enzymatically oxidized into allantoin and other products by reactive oxygen species under conditions of increased oxidative stress. Consequently, allantoin has emerged as a reliable biomarker for assessing oxidative status both in vitro and in vivo. The aim of this study was to measure allantoin and allantoin/UA ratio in patients with gout and to investigate whether these levels are higher in patients with more severe disease (tophaceous gout, presence of gouty attacks) or in patients with cardiovascular comorbidities (arterial hypertension, diabetes, dyslipidemia).

Methods: Clinical data and frozen serum samples were obtained from 154 patients with gout and 47 healthy controls. Allantoin levels in serum were determined using UHPLC-MS/MS1. In addition to allantoin levels, the allantoin/UA ratio was calculated. Serum concentrations of CRP, creatinine, UA, and lipid profile were also measured. Data are presented as medians with interquartile range [IQR]. Differences between groups were evaluated using the Wilcoxon signed-rank test. Pearson correlation coefficient was used to correlate log-transformed values with log-transformed CRP.

Results: Serum allantoin and the allantoin/UA ratio were significantly increased in patients with tophaceous gout compared to those without tophi (3.37 [1.91] vs. 2.71 [1.69], p = 0.009, and 0.008 [0.005] vs. 0.006 [0.005], p = 0.022) (Fig. 1). In patients who reported a gouty attack within the last five years, allantoin levels were significantly elevated (2.90 [2.11] vs. 2.62 [1.37], p = 0.05), showing a slight upward trend with the number of attacks. Patients with gout and concomitant arterial hypertension exhibited significantly increased levels of allantoin and the allantoin/UA ratio (3.65 [2.11] vs. 2.70 [1.34], p = 0.008, and 0.008 [0.006] vs. 0.006 [0.004], p = 0.013) (Fig. 2). No significant differences in allantoin or the allantoin/UA ratio were observed in patients with gout and other comorbidities (diabetes, dyslipidemia). Healthy controls had significantly lower levels of allantoin and the allantoin/UA ratio compared to gout patients (1.35 [3.32] vs. 2.8 [15.97], p < 0.001, and 0.004 [0.003] vs. 0.007 [0.005], p < 0.001) (Fig. 3). Allantoin and the allantoin/UA ratio were positively associated with CRP (r = 0.351, p < 0.001, and r = 0.295, p < 0.001).

Conclusion: We observed significantly elevated levels of serum allantoin and the allantoin/UA ratio in patients with more advanced gout characterized by the presence of tophi and in patients with gout and arterial hypertension. Patients who experienced a gouty attack within the last five years exhibited significantly higher levels of allantoin. The level of allantoin correlated with disease severity, as indicated by the presence of tophi, gouty attacks, and arterial hypertension. These findings suggest that higher levels of oxidative stress may contribute to increased cardiovascular risk and mortality in patients with gout, particularly in those with severe disease.

Supported by: Ministry of Health, Czech Republic (NU22-01-00465, 023728).

References:
1. Kozlik P et al. Anal Biochem. 2020;589:113509

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: L. Hasikova: None; P. Kozlik: None; K. Kalikova: None; P. Dusek: None; M. Pavlikova: None; B. Stiburkova: None; J. Závada: AbbVie/Abbott, 1, AstraZeneca, 6, Eli Lilly, 6, Sanofi, 6, Sobi, 6, UCB, 6.

To cite this abstract in AMA style:

Hasikova L, Kozlik P, Kalikova K, Dusek P, Pavlikova M, Stiburkova B, Závada J. Elevated Serum Allantoin and Allantoin/uric Acid Ratio as Indicators of Oxidative Stress in Severe Gout and Cardiovascular Comorbidities [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/elevated-serum-allantoin-and-allantoin-uric-acid-ratio-as-indicators-of-oxidative-stress-in-severe-gout-and-cardiovascular-comorbidities/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elevated-serum-allantoin-and-allantoin-uric-acid-ratio-as-indicators-of-oxidative-stress-in-severe-gout-and-cardiovascular-comorbidities/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology